Peptide signaling
A signaling peptide can bind a receptor and change what a cell does. In metabolic research, investigators study those signals in cells, in animals, and, for some approved medicines, in human trials run by the manufacturers of those medicines.
A receptor and a pathway are general biology. They do not identify the contents of a research vial or show that a vial behaves like a published preparation.
Incretin research
Incretin hormones, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are released in relation to meals and take part in glucose control. Daniel Drucker reviewed that biology in Cell Metabolism in 2006, including the development of medicines based on incretin pathways.
That review is about the hormones and about medicines developed as drugs. It is not a study of a research-catalogue vial.
Preclinical findings and human evidence
A cell study or an animal study can report a change under its own conditions. That finding does not automatically transfer to people. Human evidence, where it exists, comes from studies of defined products under a protocol, not from a catalogue page.
Where an approved medicine shares a name with a research compound, the approved medicine is a regulated product with its own manufacturer, dose, and prescribing rules. A BioCore Central listing is not that medicine.
Catalogue listings
Semaglutide, tirzepatide, and retatrutide appear in the research catalogue. On this site they are research materials. They are not offered as approved medicines, and this article does not provide administration instructions.